TY - JOUR T1 - Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 326 LP - 332 DO - 10.1136/annrheumdis-2014-205675 VL - 74 IS - 2 AU - Alexis Ogdie AU - YiDing Yu AU - Kevin Haynes AU - Thorvardur Jon Love AU - Samantha Maliha AU - Yihui Jiang AU - Andrea B Troxel AU - Sean Hennessy AU - Steven E Kimmel AU - David J Margolis AU - Hyon Choi AU - Nehal N Mehta AU - Joel M Gelfand Y1 - 2015/02/01 UR - http://ard.bmj.com/content/74/2/326.abstract N2 - Objectives We aimed to quantify the risk of major adverse cardiovascular events (MACE) among patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA) and psoriasis without known PsA compared with the general population after adjusting for traditional cardiovascular risk factors.Methods A population-based longitudinal cohort study from 1994 to 2010 was performed in The Health Improvement Network (THIN), a primary care medical record database in the UK. Patients aged 18–89 years of age with PsA, RA or psoriasis were included. Up to 10 unexposed controls matched on practice and index date were selected for each patient with PsA. Outcomes included cardiovascular death, myocardial infarction, cerebrovascular accidents and the composite outcome (MACE). Cox proportional hazards models were used to calculate the HRs for each outcome adjusted for traditional risk factors. A priori, we hypothesised an interaction between disease status and disease-modifying antirheumatic drug (DMARD) use.Results Patients with PsA (N=8706), RA (N=41 752), psoriasis (N=138 424) and unexposed controls (N=81 573) were identified. After adjustment for traditional risk factors, the risk of MACE was higher in patients with PsA not prescribed a DMARD (HR 1.24, 95% CI 1.03 to 1.49), patients with RA (No DMARD: HR 1.39, 95% CI 1.28 to 1.50, DMARD: HR 1.58, 95% CI 1.46 to 1.70), patients with psoriasis not prescribed a DMARD (HR 1.08, 95% CI 1.02 to 1.15) and patients with severe psoriasis (DMARD users: HR 1.42, 95% CI 1.17 to 1.73).Conclusions Cardiovascular risk should be addressed with all patients affected by psoriasis, PsA or RA. ER -